Metabolic Volumetric Parameters in <sup>11</sup>C-Choline PET/MR Are Superior PET Imaging Biomarkers for Primary High-Risk Prostate Cancer

Tseng, Jing-Ren; Yang, Lan-Yan; Lin, Yu-Chun; Liu, Chung-Yi; Pang, See-Tong; Hong, Ji-Hong; Yen, Tzu‐Chen; Wang, Li-Jen

doi:10.1155/2018/8945130

Cited by 12 publications

(13 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… Ferda et al [ 42 ] 2018 Czech Republic Retrospective 63.2 (47–78) 100 NA Restaging NA 18F-choline 100 Detection of disease PET/MRI with 18F-choline is a valuable tool in evaluation of restaging in patients with PCa, with high detection rate even in those with a low serum PSA level. Tseng et al [ 43 ] 2018 Taiwan Retrospective 70 (52–84) 31 30.56 ng/mL (47.5–591.9) Staging None 11C-Choline 31 Imaging interpretation Semiquantitative PET and MRI data are connected with the prognosis. Jena et al [ 44 ] 2018 India Retrospective 64 ± 1 82 NA Staging None 68Ga-PSMA-11 82 Detection of disease High diagnostic accuracy in primary tumors by using PET/MRI.…”

Section: Resultsmentioning

confidence: 99%

“…The majority of them were focused on 68Ga-PSMA-11 ( n = 32 studies), while 2 were based on 18F-PSMA [ 31 , 33 ]. Radiolabeled choline PET/MRI was employed in the staging for 8/16 (50%) [ 11 – 14 , 17 , 29 , 43 , 53 ], while radiolabeled PSMA in 16/34 (47%) papers [ 16 , 18 , 27 , 31 , 35 – 37 , 40 , 44 – 49 , 54 ]. Conversely, 5/16 (31%) [ 9 , 21 , 39 , 42 , 51 ] and 11/34 (32%) articles [ 8 , 23 , 25 , 26 , 28 , 30 , 32 , 34 , 52 , 56 ] were focused on the resting phase for radiolabeled choline and PSMA, respectively.…”

Section: Resultsmentioning

confidence: 99%

“…Six articles considered the image acquisition protocol [ 19 , 23 , 24 , 37 , 48 , 53 ], four discussed technical aspects [ 15 , 22 , 41 , 55 ], and eight focused on the interpretation of images obtained with PET/MRI [ 9 , 12 , 17 , 27 , 36 , 43 , 49 , 50 ].…”

Section: Resultsmentioning

confidence: 99%

“…Wetter et al [ 9 ] found an inverse correlation between ADC and SUV in bone metastases. Uslu-Besli et al [ 49 ] and Tseng et al [ 43 ] likewise reported an inverse correlation between the maximum SUV and the metabolic tumor volume, between uptake volume product and the ADC in primary tumor, respectively. Wetter et al [ 12 ], on the other hand, found no correlation between ADC and SUV in primary cancer.…”

Section: Resultsmentioning

confidence: 99%

See 3 more Smart Citations

PET/MRI in prostate cancer: a systematic review and meta-analysis

Evangelista

Zattoni

Cassarino

et al. 2020

Eur J Nucl Med Mol Imaging

105

View full text Add to dashboard Cite

Aim In recent years, the clinical availability of scanners for integrated positron emission tomography (PET) and magnetic resonance imaging (MRI) has enabled the practical potential of multimodal, combined metabolic-receptor, anatomical, and functional imaging to be explored. The present systematic review and meta-analysis summarize the diagnostic information provided by PET/MRI in patients with prostate cancer (PCa). Materials and methods A literature search was conducted in three different databases. The terms used were “choline” or “prostate-specific membrane antigen - PSMA” AND “prostate cancer” or “prostate” AND “PET/MRI” or “PET MRI” or “PET-MRI” or “positron emission tomography/magnetic resonance imaging.” All relevant records identified were combined, and the full texts were retrieved. Reports were excluded if (1) they did not consider hybrid PET/MRI; or (2) the sample size was < 10 patients; or (3) the raw data were not enough to enable the completion of a 2 × 2 contingency table. Results Fifty articles were eligible for systematic review, and 23 for meta-analysis. The pooled data concerned 2104 patients. Initial disease staging was the main indication for PET/MRI in 24 studies. Radiolabeled PSMA was the tracer most frequently used. In primary tumors, the pooled sensitivity for the patient-based analysis was 94.9%. At restaging, the pooled detection rate was 80.9% and was higher for radiolabeled PSMA than for choline (81.8% and 77.3%, respectively). Conclusions PET/MRI proved highly sensitive in detecting primary PCa, with a high detection rate for recurrent disease, particularly when radiolabeled PSMA was used.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

PET/MRI in prostate cancer: a systematic review and meta-analysis

Evangelista

Zattoni

Cassarino

et al. 2020

Eur J Nucl Med Mol Imaging

105

View full text Add to dashboard Cite

show abstract

“…While 18 F isotopes have the benefits of longer half-lives thereby negating the need for an onsite cyclotron, their use has been limited significantly due to urinary excretion, which obfuscates the prostatic bed and periprostatic tissues. There have been relatively few studies of 11 C and 18 F choline PET/MRIs in CaP, which have shown promise in terms of improved accuracy per lesion as well as per patient in the PET/MRI model as compared to the mpMRI model only (27)(28)(29)(30).…”

Section: C-cholinementioning

confidence: 99%

MRI/PET Imaging in elevated PSA and localized prostate cancer: a narrative review

et al. 2021

View full text Add to dashboard Cite

Objective: To review the recent milestones in MRI and PET based imaging and evaluate their evolving role in the setting of elevated PSA as well as localized prostate cancer. Background:The importance of multiparametric MRI (mpMRI) and PET based imaging for the diagnosis and staging of prostate cancer cannot be understated. Accurate staging has become another significant milestone with the use of PET scans, particularly with prostate specific radiotracers like 68-Gallium Prostate Specific Membrane Antigen (68Ga-PSMA). Integrated PET/MRI systems are commercially available and can be modulated to evaluate the unique needs of localized as well as recurrent prostate cancer.Methods: A literature search was performed using PubMed and Google Scholar using the MeSH compliant and other keywords that included prostate cancer, PSA, mpMRI, PET CT, PET/MRI.Conclusions: mpMRI has now established itself as the gold-standard of local prostate imaging and has been incorporated into international guidelines as part of the diagnostic work-up of prostate cancer. PSMA PET/CT has shown superiority over conventional imaging even in staging of localized prostate cancer based on recent randomized control data. Imaging parameters from PET/MRI have been shown to be associated with malignancy, Gleason score and tumour volume. As mpMRI and PSMA PET/CT become more ubiquitous and established; we can anticipate more high-quality data, cost optimization and increasing availability of PET/MRI to be ready for primetime in localized prostate cancer.

show abstract

Utility of radiomic zones for risk classification and clinical outcome predictions using supervised machine learning during simultaneous ¹¹C‐choline PET/MRI acquisition in prostate cancer patients

Tran

Teo

et al. 2021

Medical Physics

View full text Add to dashboard Cite

Purpose In most radiomic studies related to cancer research, the traditional tumor‐centric view has predominated. In this retrospective study, we go beyond the single‐tumor region and investigate the utility of proposed radiomic zones for risk classification and clinical outcome predictions using radiomic features extracted from 11C‐choline positron emission tomography (PET) imaging and supervised machine learning in prostate tumors. Materials and Methods Seventy‐seven prostate tumors were selected and delineated. The prostate organ was divided into three radiomic zones, with zone‐1 being the metabolic tumor zone, zone‐2 the proximal peripheral tumor zone, and zone‐3 the extended peripheral tumor zone. LIFEx was used for PET‐radiomic feature extraction. Risk groups were created using Gleason scores (GS), prostate‐specific antigen (PSA) levels, clinical TNM staging, and progression‐free survival (PFS). Random forest (RF) and AdaBoost advanced machine learning algorithms were used for supervised machine learning. Accuracy, positive predictive value, area under the receiver operating characteristic curve (AreaROC), and other metrics were calculated for comparisons of predictive performance between zones. Results For the GS risk classification group, the accuracies of risk classification predictions were 71%, 71%, and 67% using RF and 65%, 64%, and 63% using AdaBoost for zones −1, −2, and −3, respectively. For the PSA group, the accuracies of risk classification predictions were 74%, 65%, and 64% using RF and 76%, 66%, and 67% using AdaBoost for zones −1, −2, and −3, respectively. For the TNM group, the accuracies of risk classification predictions were 68%, 76%, and 78% using RF and 66%, 75%, and 80% using AdaBoost for zones −1, −2, and −3, respectively. For the PFS group, the accuracies of clinical outcome predictions were 77%, 75%, and 83% using RF and 77%, 74%, and 83% using AdaBoost in zones −1, −2, and −3, respectively. Conclusions We proposed three radiomic zones with different standard uptake value characteristics and created four risk groups of prostate cancer patients for testing this idea. We showed that these radiomic zones have different predicting strengths in classifying risk groups and might allow us to identify a radiomic zone with higher accuracy for patient outcome prediction.

show abstract

Metabolic Volumetric Parameters in ¹¹C-Choline PET/MR Are Superior PET Imaging Biomarkers for Primary High-Risk Prostate Cancer

Cited by 12 publications

References 31 publications

PET/MRI in prostate cancer: a systematic review and meta-analysis

PET/MRI in prostate cancer: a systematic review and meta-analysis

MRI/PET Imaging in elevated PSA and localized prostate cancer: a narrative review

Utility of radiomic zones for risk classification and clinical outcome predictions using supervised machine learning during simultaneous ¹¹C‐choline PET/MRI acquisition in prostate cancer patients

Contact Info

Product

Resources

About

Metabolic Volumetric Parameters in 11C-Choline PET/MR Are Superior PET Imaging Biomarkers for Primary High-Risk Prostate Cancer

Cited by 12 publications

References 31 publications

PET/MRI in prostate cancer: a systematic review and meta-analysis

PET/MRI in prostate cancer: a systematic review and meta-analysis

MRI/PET Imaging in elevated PSA and localized prostate cancer: a narrative review

Utility of radiomic zones for risk classification and clinical outcome predictions using supervised machine learning during simultaneous 11C‐choline PET/MRI acquisition in prostate cancer patients

Contact Info

Product

Resources

About

Metabolic Volumetric Parameters in ¹¹C-Choline PET/MR Are Superior PET Imaging Biomarkers for Primary High-Risk Prostate Cancer

Utility of radiomic zones for risk classification and clinical outcome predictions using supervised machine learning during simultaneous ¹¹C‐choline PET/MRI acquisition in prostate cancer patients